Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Hruby and Mac Hadley (University of Arizona, USA) in 19871989 Original development program Competitive Technologies Palatin Technologies , later spun off into PT-141 (bremelanotide) Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than -MSH, longer half-life) Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996) In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism Approximately 100+ publications in PubMed
Sci Rep 12 , 15975 (2022)
Solving Medicare solvency is intertwined with controlling healthcare inflation overall through innovation, prevention, and tough choices about paying for new therapies
91 , e1044316 (2017)
